INSM Insmed Incorporated
As of 3:59:00 PM ET · 2 days old· Couldn’t refresh just now; showing the last price
Loading chart…
- Open
- $113.60
- Previous close
- $111.59
- Day range
- 111.97 – 116.37
- 52-week range
- 90.39 – 212.75
- Volume
- 5.2M
- Avg volume (3M)
- 2.9M
- Market cap
- $24.7B
- P/E (TTM)
- −17.54
- EPS (TTM)
- −$4.10
- Beta
- —
- Dividend yield
- 0.00%
- Next earnings
- —
- Ex-dividend
- —
- Sector
- Healthcare
About Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases. Its current portfolio includes an approved treatment for Mycobacterium avium complex lung disease, along with clinical-stage programs focused on pulmonary and inflammatory conditions. The company’s pipeline emphasizes innovative approaches such as oral therapies and inhaled medicines designed to address difficult-to-treat respiratory disorders. Insmed also conducts research across multiple scientific platforms, including protein engineering and other advanced drug-development technologies. Headquartered in Bridgewater, New Jersey, Insmed serves patients and healthcare providers in the United States, Europe, Japan, and other international markets, positioning itself as a specialist in rare-disease and specialty respiratory treatment.
| Quarter | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Oct 29, 2026(after close) | −$0.35 | −$0.46 | +31.4% |
| Aug 6, 2026(after close) | −$0.68 | −$0.06 | −91.2% |
| May 7, 2026(after close) | −$1.00 | −$0.76 | −24.0% |
| Mar 13, 2026(after close) | $0.05 | $0.07 | +40.0% |
| Feb 19, 2026(after close) | −$1.17 | −$1.54 | +31.6% |
INSM doesn’t pay a dividend.
INSM news and filings
Loading filings…
Filings from SEC EDGAR.